Stay updated on Pembrolizumab Combo in Resectable NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Combo in Resectable NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Combo in Resectable NSCLC Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    Footer revision label updated from v3.3.1 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2025-11-30T16:31:36.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    Added notes clarifying that publications can be entered voluntarily and may be auto-filled from PubMed; a revision label v3.3.1 was added, replacing the former v3.2.0 wording.
    Difference
    0.2%
    Check dated 2025-11-23T14:50:32.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    Removed the government funding status notice from the page. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-11-16T14:26:02.000Z thumbnail image
  5. Check
    39 days ago
    Change Detected
    Summary
    The Study Details page appears unchanged between screenshots; there are no alterations to the trial title, interventions, outcomes, or eligibility criteria.
    Difference
    0.1%
    Check dated 2025-11-02T00:54:41.000Z thumbnail image
  6. Check
    68 days ago
    Change Detected
    Summary
    Major update: region name updated from Rhone-Alpes to Auvergne-Rhône-Alpes with a new Pierre-Bénite entry; page version bumped to v3.2.0; added government operating-status notice.
    Difference
    3%
    Check dated 2025-10-04T12:14:07.000Z thumbnail image
  7. Check
    75 days ago
    Change Detected
    Summary
    The page has been updated to version v3.1.0 and several related topics (MedlinePlus topics on drug safety, counterfeit drugs, pharmaceutical preparations, and substandard drugs) have been removed.
    Difference
    0.2%
    Check dated 2025-09-27T07:52:26.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Combo in Resectable NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Resectable NSCLC Clinical Trial page.